The cellular origin of mantle cell lymphoma

被引：61

作者：

Bertoni, Francesco

Ponzoni, Maurilio

机构：

[1] IOSI, Expt Oncol Lab, CH-6500 Bellinzona, Switzerland

[2] Ist Sci San Raffaele, Pathol Unit, Unit Lymphoid Malignancies, Milan, Italy

来源：

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY | 2007年 / 39卷 / 10期

关键词：

CCND1; iminunoglobulin; somatic hypermutation; chromosomal translocation; NFKB; mTOR;

D O I：

10.1016/j.biocel.2007.04.026

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Mantle cell lymphoma accounts for 5-10% of all non-Hodgkin's lymphomas and it has one the worst prognosis among all lymphomas. There is no therapy that can be considered as standard. Mantle cell lymphoma can show different "architectural" patterns as well different morphologic variants. Mantle cell lymphoma is believed to derive from marginal zone or peripheral blood memory B-cells. The immunophenotype of the neoplastic cells reflect the phenotype of a mature B-cell, even if mantle cell lymphoma cells are typically CD5+ and CD23-. Mantle cell lymphoma is characterized by the deregulated expression of cyclins D, mainly of cyclin D1, which is targeted by the t(11;14)(q13;q32) chromosomal translocation, the genetic hallmark of the disease. In this review will summarize the main morphologic and immunophenotypic features of the neoplastic cells, and the genetics and biology underlying the disease. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1747 / 1753

页数：7

共 29 条

[1] Update on the molecular biology of mantle cell lymphoma [J].

Bertoni, F ;

Rinaldi, A ;

Zucca, E ;

Cavalli, F .

HEMATOLOGICAL ONCOLOGY, 2006, 24 (01) :22-27

[2] Molecular basis of mantle cell lymphoma [J].

Bertoni, F ;

Zucca, E ;

Cotter, FE .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (02) :130-140

[3] ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances [J].

Camacho, E ;

Hernández, L ;

Hernández, S ;

Tort, F ;

Bellosillo, B ;

Beà, S ;

Bosch, F ;

Montserrat, E ;

Cardesa, A ;

Fernández, PL ;

Campo, E .

BLOOD, 2002, 99 (01) :238-244

[4] Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation [J].

Chen, Linfeng ;

Juszczynski, Przemyslaw ;

Takeyama, Kunihiko ;

Aguiar, Ricardo C. T. ;

Shipp, Margaret A. .

BLOOD, 2006, 108 (10) :3428-3433

[5] Mantle cell lymphoma: At last, some hope for successful innovative treatment strategies [J].

Fisher, RI .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :657-658

[6] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J].

Fisher, Richard I. ;

Bernstein, Steven H. ;

Kahl, Brad S. ;

Djulbegovic, Benjamin ;

Robertson, Michael J. ;

de Vos, Sven ;

Epner, Elliot ;

Krishnan, Amrita ;

Leonard, John P. ;

Lonial, Sagar ;

Stadtmauer, Edward A. ;

O'Connor, Owen A. ;

Shi, Hongliang ;

Boral, Anthony L. ;

Goy, Andre .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4867-4874

[7] Cyclin D1-negative mantle cell lymphoma:: a clinicopathologic study based on gene expression profiling [J].

Fu, K ;

Weisenburger, DD ;

Greiner, TC ;

Dave, S ;

Wright, G ;

Rosenwald, A ;

Chiorazzi, M ;

Iqbal, J ;

Gesk, S ;

Siebert, R ;

De Jong, D ;

Jaffe, ES ;

Wilson, WH ;

Delabie, J ;

Ott, G ;

Dave, BJ ;

Sanger, WG ;

Smith, LM ;

Rimsza, L ;

Braziel, RM ;

Müller-Hermelink, HK ;

Campo, E ;

Gascoyne, RD ;

Staudt, LM ;

Chan, WC .

BLOOD, 2005, 106 (13) :4315-4321

[8] Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma [J].

Greiner, TC ;

Dasgupta, C ;

Ho, VV ;

Weisenburger, DD ;

Smith, LM ;

Lynch, JC ;

Vose, JM ;

Fu, K ;

Armitage, JO ;

Braziel, RM ;

Campo, E ;

Delabie, J ;

Gascoyne, RD ;

Jaffe, ES ;

Muller-Hermelink, HK ;

Ott, G ;

Rosenwald, A ;

Staudt, LM ;

Im, MY ;

Karaman, MW ;

Pike, BL ;

Chan, WC ;

Hacia, JG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2352-2357

[9]

Kouroukis CT, 2003, J CLIN ONCOL, V21, P1740, DOI 10.1200/JCO.2003.09.057

[10] In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphoma [J].

Lacrima, K ;

Valentini, A ;

Lambertini, C ;

Taborelli, M ;

Rinaldi, A ;

Zucca, E ;

Catapano, C ;

Cavalli, F ;

Gianella-Borradori, A ;

MacCallum, DE ;

Bertoni, F .

ANNALS OF ONCOLOGY, 2005, 16 (07) :1169-1176

← 1 2 3 →